Sm 14

Drug Profile

Sm 14

Alternative Names: Anti-schistosomiasis vaccine; rSm14; Sm-14; Sm14 vaccine; Snail fever vaccine

Latest Information Update: 01 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oswaldo Cruz Foundation
  • Developer Orygen Biotecnologia; Oswaldo Cruz Foundation
  • Class Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Schistosomiasis

Most Recent Events

  • 31 Jan 2017 Oswaldo Cruz Foundation and Orygen Biotecnologia complete enrolment in the phase II trial for Schistosomiasis in Senegal (NCT03041766)
  • 06 Dec 2016 Phase-II clinical trials in Schistosomiasis (In volunteers, Treatment-experienced) in Senegal (IM) (NCT03041766)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top